Synlogic, Inc. (NASDAQ:SYBX) was founded in 2013 and is headquartered in Cambridge, Massachusetts, with 63 full-time employees. It is a clinical stage biopharmaceutical company that focuses on the discovery and development of synthetic biological drugs in the United States to treat metabolism, Inflammation and cancer diseases.
Synlogic, Inc. (SYBX):
Synlogic’s main treatment options include:
1. SYNB1020, an oral therapy, is undergoing phase I clinical trials for the treatment of patients with liver disease and hepatic encephalopathy and urea cycle disorders.
2. SYNB1618, an oral therapy used in a phase I/IIa clinical trial for the treatment of phenylketonuria.
Synlogic is also involved in the development of discovery stage candidate products for congenital metabolic errors, including maple diabetes, isovaleric acidemia and organic acidemia.
Synlogic signed a cooperation agreement with AbbVie S.à.rl to develop synthetic biologic drugs for the treatment of inflammatory bowel disease; and cooperated with Ginkgo Bioworks to develop new in vivo drugs for the treatment of neurological and liver diseases.